Fructose diphosphate sodium oral solution

This product is a cell metabolite existing in the human body, which can regulate the activity of multiple enzyme systems in glucose metabolism. It is reported that exogenous sodium fructose diphosphate can increase the concentration of adenosine triphosphate and creatine phosphate in cells by activating the activity of phosphofructokinase and pyruvate kinase, promote the influx of potassium ions, and is beneficial to the energy metabolism and glucose utilization of cells under ischemic and hypoxic conditions. It can thus reduce the damage to ischemic myocardium.

The main ingredient of this product is sodium fructose diphosphate.

This product is a colorless or slightly yellow clear liquid with a slightly sweet taste and orange aroma.

1. Used for the treatment of myocarditis, cardiomyopathy and coronary heart disease; 2. Used for the treatment of hypoxic-ischemic encephalopathy, cerebral ischemia, high fever or hypoxic craniocerebral injury; 3. Used for the treatment of fatty liver, acute and chronic hepatitis, cirrhosis and alcoholic liver disease.

Oral administration, 1-2 g (10-20 ml) each time, 2-3 times a day.

The main manifestations are mild symptoms of the digestive system, such as abdominal distension, nausea, upper abdominal burning sensation, loose stools, etc. Patients can generally tolerate it and there is no need to stop the medication.

It is contraindicated in patients with hyperphosphatemia and renal failure.

This product should be used alone and should not be dissolved in other drugs, especially in alkaline solutions and calcium salts.

Store tightly closed at below 30°C.

According to C6H11O12P2Na3 100ml:10g

Two years

Beijing Huajin Pharmaceutical Co., Ltd.

• Founded in:

  1992-07-20

• Address:

  No. 01, 1st to 3rd Floor, Building 3, No. 31 Xinggu Road, Xinggu Street, Pinggu District, Beijing

• Tax NO.:

  91110105600024567L

• Registered Funds:

  7.8864 million yuan

• Website:

  Log in to view

• Email:

  Log in to view